Q-Line Biotech Limited
ListedSMEHealthcare · NSE
Q-Line Biotech Limited is a healthcare diagnostics company engaged in the manufacturing and supply of In-Vitro Diagnostic (IVD) products, pathology reagents, rapid test kits, and laboratory equipment for hospitals, diagnostic laboratories, and healthcare institutions across India. Established in 2010, the company focuses on affordable diagnostic solutions and operates in the medical diagnostics and healthcare consumables segment, with its proposed IPO planned for listing on the NSE EMERGE SME platform.
Price Band
₹326 – ₹343
Issue Size
₹625.32 L Cr
Lot Size
400 shares
GMP
₹95
+27.7%
Est. Listing
₹438
at current GMP
Subscribed
102.49x
overall
Open
21 May 2026
Close
25 May 2026
Allotment
26 May 2026
Refund
27 May 2026
Demat Credit
28 May 2026
Listing
29 May 2026
Last updated 4 months ago
Overall Subscription
102.49x
Total Demand
QIB Multiplier
123.94x
Institutions & Funds
NII / HNI
146.33x
High Net-Worth
Retail (RII)
71.44x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 1,188,000 | 147,237,200 | 123.94x |
| NIB | 891,600 | 130,466,800 | 146.33x |
| HNIs(10L +) | 594,400 | 106,289,200 | 178.82x |
| HNIs (2-10L) | 297,200 | 24,177,600 | 81.35x |
| RETAIL | 2,079,200 | 148,541,600 | 71.44x |
| Total | 5,050,400 | 556,712,400 | 102.49x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| QIB | — | 197 | 0.00x |
| NIB | — | 49,781 | 0.00x |
| RETAIL | 2,599 | 185,677 | 71.44x |
| HNIs(10L +) | 495 | 31,162 | 62.95x |
| HNIs (2-10L) | 248 | 18,619 | 75.08x |
| Total Applications | 3,342 | 285,436 | 85.41x |
Day-Wise Subscription Progress
About Q-Line Biotech Limited Public Issue & Market Profile
Q-Line Biotech Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹62,53,200 Crores. The shares are offered at a price band of ₹326 to ₹343 per equity share on NSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Bidding & Quota Instructions:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 400 shares (approx. ₹1,37,200 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment Reconciliation Schedule:
Allotment reconciliation will be managed by Purva Sharegistry India Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-05-28, while un-allotted funds or UPI block mandates will be released on 2026-05-27.
Frequently Asked Questions
What is the issue size and price band for Q-Line Biotech Limited IPO?
The Q-Line Biotech Limited IPO aggregate issue size is ₹62,53,200 Crores with an equity price band set at ₹326 to ₹343 per equity share. The retail lot size is 400 shares requiring a minimum capital outlay of approx. ₹1,37,200.
How can I check Q-Line Biotech Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. You can track QIB, NII/HNI, and Retail category multiples directly on our dedicated live subscription page.
Where will Q-Line Biotech Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Purva Sharegistry India Private Limited) and the BSE status verification website on or around 2026-05-26.